See more : Crocodile Garments Limited (0122.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Pyxis Oncology, Inc. (PYXS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pyxis Oncology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- China Tontine Wines Group Limited (0389.HK) Income Statement Analysis – Financial Results
- Polygreen Resources Co., Ltd. (8423.TWO) Income Statement Analysis – Financial Results
- Pelangio Exploration Inc. (PX.V) Income Statement Analysis – Financial Results
- Qingdao Topscomm Communication INC. (603421.SS) Income Statement Analysis – Financial Results
- Adimmune Corporation (4142.TW) Income Statement Analysis – Financial Results
Pyxis Oncology, Inc. (PYXS)
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.00M | 1.84M | 1.25M | 444.00K | 0.00 |
| Gross Profit | -2.00M | -1.84M | -1.25M | -444.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 49.59M | 86.13M | 51.05M | 9.05M | 1.22M |
| General & Administrative | 32.61M | 37.35M | 18.66M | 3.85M | 1.66M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 32.61M | 37.35M | 18.66M | 3.85M | 1.66M |
| Other Expenses | 0.00 | 0.00 | 181.00K | 0.00 | 0.00 |
| Operating Expenses | 82.20M | 123.48M | 69.72M | 12.89M | 2.88M |
| Cost & Expenses | 82.20M | 123.48M | 69.72M | 12.89M | 2.88M |
| Interest Income | 6.63M | 2.76M | 23.00K | 66.00K | 107.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.00M | 1.84M | 1.25M | 444.00K | 2.88M |
| EBITDA | -78.49M | -122.77M | -69.07M | -12.43M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -82.20M | -123.48M | -69.72M | -12.89M | -2.88M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.41M | 2.76M | -6.26M | 66.00K | 107.00K |
| Income Before Tax | -73.79M | -120.72M | -75.98M | -12.83M | -2.77M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -2.76M | 5.56M | -66.00K | -107.00K |
| Net Income | -73.79M | -117.95M | -81.54M | -12.76M | -2.67M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.85 | -3.57 | -2.53 | -0.37 | -0.08 |
| EPS Diluted | -1.85 | -3.57 | -2.53 | -0.37 | -0.08 |
| Weighted Avg Shares Out | 39.90M | 33.03M | 32.22M | 34.31M | 34.31M |
| Weighted Avg Shares Out (Dil) | 39.90M | 33.03M | 32.22M | 34.31M | 34.31M |
APEXIGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN
3 Top Penny Stocks To Watch As GSIT, OMH Stock Explode
Why Am I Losing Money With Penny Stocks? 3 Reasons
Beginner Penny Stocks Trading Mistakes: 3 to Avoid
Pyxis Oncology: Cashed Up And Entering The Clinic
Pyxis Oncology to Present at H.C. Wainwright Preclinical Cancer Drug Discovery Conference
Pyxis Oncology Announces Presentations at Upcoming Investor Conferences
Pyxis Oncology to Host Corporate Update Conference Call and Webcast on March 29, 2022
Pyxis Oncology to Present at the Jefferies London Healthcare Conference
Source: https://incomestatements.info
Category: Stock Reports